Dangers of exposure to ‚white‘ light

New study reveals: ‚White‘ light suppresses the body’s production of melatonin — a compound that adjusts our biological clock and is known for its anti-oxidant and anti-cancerous properties — more than orange light

 

Haifa, Israel (September 12, 2011) – Exposure to the light of white LED bulbs, it turns out, suppresses melatonin 5 times more than exposure to the light of High Pressure Sodium bulbs that give off an orange-yellow light. "Just as there are regulations and standards for ‚classic‘ pollutants, there should also be regulations and rules for the pollution stemming from artificial light at night," says Prof. Abraham Haim of the University of Haifa.

 

"White" light bulbs that emit light at shorter wavelengths are greater suppressors of the body’s production of melatonin than bulbs emitting orange-yellow light, a new international study has revealed.

 

Melatonin is a compound that adjusts our biological clock and is known for its anti-oxidant and anti-cancerous properties.

 

The study investigated the influence of different types of bulbs on "light pollution" and the suppression of melatonin, with the researchers recommending several steps that should be taken to balance the need to save energy and protecting public health.

 

"Just as there are regulations and standards for ‚classic‘ pollutants, there should also be regulations and rules for pollution stemming from artificial light at night," says Prof. Abraham Haim, head of the Center for Interdisciplinary Chronobiological Research at the University of Haifa and the Israeli partner in the research.

 

The study, titled "Limiting the impact of light pollution on human health, environment and stellar visibility" by Fabio Falchi, Pierantonio Cinzano, Christopher D. Elvidge, David M. Keith and Abraham Haim, was recently published in the Journal of Environmental Management.

 

The fact that "white" artificial light (which is actually blue light on the spectrum, emitted at wavelengths of between 440-500 nanometers) suppresses the production of melatonin in the brain’s pineal gland is already known. Also known is the fact that suppressing the production of melatonin, which is responsible, among other things, for the regulation of our biological clock, causes behavior disruptions and health problems.

 

In this study, conducted by astronomers, physicists and biologists from ISTIL- Light Pollution Science and Technology Institute in Italy, the National Geophysical Data Center in Boulder, Colorado, and the University of Haifa, researchers for the first time examined the differences in melatonin suppression in a various types of light bulbs, primarily those used for outdoor illumination, such as streetlights, road lighting, mall lighting and the like.

 

In the first, analytical part of the study, the researchers, relying on various data, calculated the wavelength and energy output of bulbs that are generally used for outdoor lighting. Next, they compared that information with existing research regarding melatonin suppression to determine the melatonin suppression level of each bulb type.

 

Taking into account the necessity for artificial lighting in cities, as well as the importance of energy-saving bulbs, the research team took as a reference point the level of melatonin suppression by a high-pressure sodium (HPS) bulb, a bulb that gives off orange-yellow light and is often used for street and road lighting, and compared the data from the other bulbs to that one.

 

From this comparison it emerged that the metal halide bulb, which gives off a white light and is used for stadium lighting, among other uses, suppresses melatonin at a rate more than 3 times greater than the HPS bulb, while the light-emitting diode (LED) bulb, which also gives off a white light, suppresses melatonin at a rate more than 5 times higher than the HPS bulb.

 

"The current migration from the now widely used sodium lamps to white lamps will increase melatonin suppression in humans and animals," the researchers say.

 

The researchers make some concrete suggestions that could alter the situation without throwing our world into total darkness, but first and foremost, they assert that it is necessary to understand that artificial light creates "light pollution" that ought to be addressed in the realms of regulation and legislation.

 

Their first suggestion of course, is to limit the use of "white" light to those instances where it is absolutely necessary. Another suggestion is to adjust lampposts so that their light is not directed beyond the horizon, which would significantly reduce light pollution. They also advise against "over-lighting", using only the amount of light needed for a task, and, of course, to simply turn off lighting when not in use – "Just like we all turn off the light when we leave the room. This is the first and primary way to save energy," the researchers say.

 

"Most Italian regions have legislations to lower the impact of light pollution, but they still lack a regulation on the spectrum emitted by lamps. Unless legislation is updated soon, with the current trend toward sources as white LEDs, which emit a huge amount of blue light, we will enter a period of elevated negative effects of light at night on human health and environment. Lamp manufacturers cannot claim that they don’t know about the consequences of artificial light at night," says Dr. Fabio Falchi of ISTIL.

 

"As a first step in Israel, for example, the Standards Institution of Israel should obligate bulb importers to state clearly on their packaging what wavelengths are produced by each bulb. If wavelength indeed influences melatonin production, this is information that needs to be brought to the public’s attention, so consumers can decide whether to buy this lighting or not," Prof. Haim says.

 

 


University of Haifa, 12.09.2011 (tB).

MEDICAL NEWS

COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…